Key result
Anti-TB therapy normalizes LV function within weeks in 3 cases of tuberculous myocarditis.
Why the study?
Does anti-TB therapy improve clinical status and left ventricular function in patients with tuberculous myocarditis?
Case Report (n=3)
Does anti-TB therapy improve clinical status and left ventricular function in patients with tuberculous myocarditis?
Anti-TB therapy can lead to full clinical and echocardiographic recovery in patients with tuberculous myocarditis, challenging the notion that the condition is universally fatal.
Answers are grounded in this paper and cite their sources.
May support anti-TB therapy in tuberculous myocarditis; hypothesis-generating from case reports and requires prospective validation.
Tuberculosis (TB) is a leading cause of death worldwide. It can affect any organ. However, cardiac involvement is extremely rare. Anti-TB therapy has been proved to be effective and curative in majority of TB cases except TB myocarditis, where it is found to be fatal. We describe three cases with confirmed TB with impaired left ventricular systolic function and low ejection fraction. All three cases improved clinically and left ventricular function returned to normal within a few weeks after the commencement of TB therapy.
No takes yet. Share an insight, caveat, or question.
Al-Jahdali et al. (2017) conducted a case report in Tuberculous Myocarditis (n=3). Anti-TB therapy was evaluated on Clinical improvement and normalization of left ventricular function. Anti-TB therapy led to clinical improvement and normalization of left ventricular function within a few weeks in three cases of confirmed tuberculous myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: